Guardant Health Inc

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Guardant Health reports robust Q1 earnings, eyes growth opportunities

Guardant Health's Q1 2023 earnings call showcased strong financial performance, advancements in screening technology, and a focus on operational efficiency. The company's revenue growth, successful Medicare reimbursement, and strategic guidance raise optimism for future growth. Challenges lie in managing expenses and commercial investments post-FDA approval.

Guardant Health reports robust Q2 results and eyes international expansion

Guardant Health's Q2 performance reflects strong revenue growth and test volume increase, with a focus on achieving cash flow breakeven.
The company's strengths lie in expanding payer coverage, advancing Shield blood tests, and seeing growth in the MRD market.
Challenges include legal expenses, low lung cancer screening rates, and managing cash burn, while opportunities exist in Japan market expansion and EMR integration.
Overall, Guardant Health is poised for growth with a strategic focus on innovation, market expansion, and financial sustainability.

Guardant Health reports strong Q3 performance, eyes international expansion

Guardant Health's Q3 2023 showcased robust revenue growth and strong test volume performance, particularly in Precision Oncology and Guardant360.
The company's focus on innovation, payer coverage breakthroughs, and international expansion presents significant growth opportunities.
While Shield V2 faces challenges in AA detection, progress on FDA approval and sales strategy post-approval are key areas of focus.
Overall, Guardant Health's strategic investments and product advancements position it well for continued growth and market leadership.

Guardant Health reports robust revenue growth and strategic advancements

Guardant Health's strong financial performance, focus on key strengths, and management of challenges position the company for continued growth
Opportunities in revenue growth, product upgrades, and market expansion present avenues for further success
Strategic initiatives in therapy selection, MRD, and screening underscore Guardant Health's commitment to innovation and market leadership

Guardant Health excels in Q2 2024 with FDA-approved Shield test

Guardant Health's Q2 2024 performance showcased strong revenue growth, driven by the success of the Shield blood test and Guardant360. While facing challenges in cash flow, the company remains optimistic about future opportunities in the diagnostic testing market.

Guardant Health reports robust Q3 earnings, eyes international expansion

Guardant Health's Q3 2024 earnings call highlighted strong revenue growth, exceeding expectations in key segments. The company raised its full-year revenue guidance and showcased improvements in free cash flow. Shield blood test and Reveal revenue are expected to drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

PALO ALTO, Calif.--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the ASCO 2023 Gastrointestinal Cancers Symposium, January 19-21 in San Francisco.

Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers

AMC Entertainment

Global Business Travel Group I

Immunovant Inc

Maxar Technologies

Madrigal Pharmaceuticals

Mirati Therapeutics

Intellia Therapeutics

Rumble Inc

Prometheus Biosciences

Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.

These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022

PALO ALTO, Calif.--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today announced preliminary, unaudited results for the year ended December 31, 2022.

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results

PALO ALTO, Calif.--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.

Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Ginkgo Bioworks Holdings

Novavax

As we head into New Year 2023, we wanted to take a look at some of the top biotech blunders of the last several months. While many biotech stocks can hold immense profit potential, others can wipe out your accounts in the blink of an eye.

Three Pharma Stocks to Sell Before They Die

PALO ALTO, Calif. & DALLAS--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Susan G. Komen®, the world's leading breast cancer organization, announced today that they have entered into a partnership to bring the patient perspective to the development of clinical studies that help identify early-stage breast cancer patients who are at high risk of disease recurrence and may benefit from additional monitoring or therapy.

Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy

Guardant Health stock (NASDAQ: GH), a healthcare company that offers non-invasive cancer diagnosis tests, has seen a fall of 38% in a month, while it's down 70% this year.

Is A Rise Imminent For Guardant Health Stock After A 38% Fall In A Month?

On Dec. 15, the highly anticipated results of Guardant Health Inc.'s ( GH , Financial) pivotal DNA blood test trial were revealed, and the results fell short of expectations, causing the company's stock price to plummet 30%. The test managed to detect just 83% of colorectal cancers and 13% of advanced adenomas (a cancer precursor).

Guardant Health Drops 30% as Cancer Test Disappoints

Exact Sciences

The broader market lost more ground on Friday.

This Nasdaq Healthcare Stock's Pain Is Its Rival's Gain

Guardant Health Inc (NASDAQ:GH) stock plunged on Friday after the firm released results from a study of its colon cancer blood test that showed disappointing accuracy rates. Although the test accurately identified the presence of cancer or precancer 83% of the time, investors were hoping to see at least an 85% accuracy rate, Bloomberg reported.

Guardant Health stock plunges, Exact Sciences rises on contrasting colorectal cancer detection tests

Guardant Health (NASDAQ: GH ) stock dropped nearly 33% after a test of its colon-cancer screening system disappointed investors. The company's Shield blood test found 83% of cancers and 13% of pre-cancerous polyps in a trial called ECLIPSE.

Guardant Health (GH) Stock Sinks on Disappointing Blood Test Results

“We just launched a rocket and got it to the moon,” said co-chief executive Helmy Eltoukhy. “It's illogical, irrational, and people don't understand the science.

Guardant Claimed Success for Its Colon Cancer Blood Test. Investors Disagreed.

Shares of Guardant Health Inc. tanked 40% and shares of Exact Sciences Corp. rallied more than 25% in the extended session Thursday after Guardant announced results from a study using its blood test to screen for colorectal cancer that didn't appear to surpass Exact Sciences' stool-sample screening test. Guardant said that the results "pave the way for first potential FDA-approved and Medicare-reimbursed blood test for colorectal cancer screening," and that it plans to ask for U.S. Food and Drug Administration approval in early 2023.

Guardant Health stock plunges, Exact Sciences stock soars after colorectal-cancer test study results

Guardant Health Inc GH and Exact Sciences Corp EXAS shares are moving in different directions in Thursday's after-hours session. Here's a look at what's going on.

After-Hours Action: What's Going On With Guardant Health, Exact Sciences Shares? - Exact Sciences (NASDAQ:EXAS)

PALO ALTO, Calif.--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today positive results from ECLIPSE (Evaluation of ctDNA LUNAR Assay In an Average Patient Screening Episode), an over 20,000 patient registrational study evaluating the performance of its blood test for detecting colorectal cancer (CRC) in average-risk adults.

Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer

PALO ALTO, Calif.--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it has entered into a collaboration with AstraZeneca to pursue the development, regulatory approval and commercialization of the Guardant360® CDx blood test as a companion diagnostic to identify patients with ESR1-mutated metastatic breast cancer. The initiative is part of a larger strategic collaboration investigating the use of liquid biopsy as a tool to inform early therapy intervention.

Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer

PALO ALTO, Calif.--( BUSINESS WIRE )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 San Antonio Breast Cancer Symposium, December 6-10 in San Antonio, Texas. The six poster presentations highlight the use of the Guardant360® blood test and the GuardantINFORM™ real-world evidence dataset to identify critical biomarkers and acquired co-mutations, track associated treatment patterns and clinical outcomes, and monitor molecular response to therapy based on specific breast cancer driver mutations.

Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients

Guardant Health, Inc. (NASDAQ:GH ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Alex Kleban - Vice President, Investor Relations Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Securities Jack Meehan - Nephron Research Matt Sykes - Goldman Sachs Kyle Mikson - Canaccord Mark Massaro - BTIG Neel Ram - Morgan Stanley Max Masucci - Cowen Patrick Donnelly - Citi Operator Hello and welcome to today's Guardant Health Third Quarter 2022 Financial Results. My name is Alex.

Guardant Health, Inc. (GH) Q3 2022 Earnings Call Transcript

Guardant Health (GH) delivered earnings and revenue surprises of -24.41% and 0.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q3 Loss, Lags Revenue Estimates

Guardant Health Reports Third Quarter 2022 Financial Results

Is Guardant Health as obvious a bargain as this analyst makes it out to be?

Why Guardant Health Stock Fell 5.5% Today

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webca

Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022

Add another name to the list of the cancer-diagnostic company's bulls.

Why Guardant Health Topped the Market on Thursday

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health introduces GuardantINFINITY, a smart liquid biopsy providing multi-dimensional insights to advance cancer research & drug development.

Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health will showcase data at ESMO 2022 demonstrating the utility of its portfolio of blood tests for advanced-stage cancer patients.

News for Guardant Health Inc Stock (GH)